First release #HOPE4LIVER data reveals “exciting” potential of histotripsy for liver tumours

Clinical professor of radiology Mishal Mendiratta-Lala (Michigan, USA), expands on the first data release from the #HOPE4LIVER trial, presented during the FIRST@CIRSE session at this years Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting.

“We are very excited about histotripsy as a new form of liver directed treatment for liver cancer” states Mendiratta-Lala, noting that sights are set on future US Food and Drug Administration (FDA) approval to begin treating patient populations in both the USA and Europe with both primary and metastatic cancer, which she believes will “[add] another form of therapy to our arsenal”.